Business
Aeglea BioTherapeutics Appoints Hunter C. Smith to Board of Directors
AUSTIN, Texas, Nov. 16, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a clinical-stage biotechnology company developing a new generation
About this update from Spyre Therapeutics, Inc.
[{"type":"text","content":"AUSTIN, Texas, Nov. 16, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the appointment of Hunter C. Smith to its board of directors. Mr. Smith currently serves as the chief financial officer of Rhythm Pharmaceuticals.\n\"We are excited to welcome Hunter to our board of directors and to the Aeglea family,\" said Anthony Quinn, M.B Ch.B, Ph.D., president and chief executive officer of Aeglea. \"Hunter brings a wealth of experience as a biotech leader including corporate strategy, global commercial planning and product launches. His addition to our board will bring valuable experience and input as we further our mission to bring human enzyme therapies to people living with rare metabolic diseases.\"\n\"I'm excited to be joining the board of Aeglea, particularly as the company is on the cusp of pivotal data from its trial for its Arginase 1 Deficiency program next month,\" said Mr. Smith. \"I look forward to working with existing board members and the Aeglea team as they advance Aeglea toward becoming a commercial-stage company while continuing to realize the immense potential of its human enzyme therapy pipeline.\"\nMr. Smith's roles at biopharma companies include senior-level leadership, corporate strategy and financial oversight of commercial operations. Mr. Smith has served as the chief financial officer of Rhythm Pharmaceuticals since 2017 and served as interim chief executive officer from March to July 2020. Prior to joining Rhythm, Mr. Smith was vice president, finance and chief financial officer of Celgene Corporation's inflammation and immunology business unit where he provided financial and strategic leadership for the global launch of Otezla®. Prior to Celgene, Mr. Smith held roles of increasing responsibility at Bunge Limited. He holds an M.B.A in finance from NYU's Stern School of Business and a B.A. in history, with honors, from Northwestern University.\nAbout Aeglea BioTherapeuticsAeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare metabolic diseases with limited treatment options. Aeglea's lead product candidate, pegzilarginase, is in a pivota...